Novartis (NVS) IRANNOTICE Disclosure regarding Iran Threat Reduction and Syria Human Rights Act

Novartis AG

Novartis Campus

4002 Basel

Switzerland

Telephone : +41 61 324 1111

US Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

January 29, 2020

Re:    Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

Ladies and Gentlemen:

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission on January 29, 2020.

Respectfully submitted,

Novartis AG

/s/ SHANNON THYME KLINGER	/s/ HARRY KIRSCH
Shannon Thyme Klinger	Harry Kirsch
General Counsel	Chief Financial Officer
Novartis Group	Novartis Group